Chemed Corp. (CHE) Receives Consensus Recommendation of “Hold” from Brokerages
Chemed Corp. (NYSE:CHE) has received a consensus rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $214.50.
CHE has been the subject of a number of research analyst reports. TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Royal Bank Of Canada reiterated a “hold” rating and issued a $209.00 target price on shares of Chemed Corp. in a research note on Friday, September 1st. KeyCorp initiated coverage on shares of Chemed Corp. in a research note on Monday, August 28th. They issued a “sector weight” rating for the company. Zacks Investment Research cut shares of Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 22nd. Finally, Oppenheimer Holdings, Inc. lifted their target price on shares of Chemed Corp. from $200.00 to $220.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th.
In related news, Director Patrick P. Grace sold 500 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $201.48, for a total value of $100,740.00. Following the completion of the transaction, the director now owns 4,515 shares in the company, valued at approximately $909,682.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Spencer S. Lee sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $197.46, for a total transaction of $197,460.00. Following the completion of the transaction, the insider now owns 37,809 shares of the company’s stock, valued at approximately $7,465,765.14. The disclosure for this sale can be found here. Insiders sold a total of 16,500 shares of company stock valued at $3,315,600 in the last 90 days. 5.32% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the stock. USA Financial Portformulas Corp bought a new position in Chemed Corp. in the 2nd quarter worth approximately $292,000. Dynamic Technology Lab Private Ltd bought a new position in Chemed Corp. in the 2nd quarter worth approximately $648,000. Piedmont Investment Advisors LLC bought a new position in Chemed Corp. in the 2nd quarter worth approximately $711,000. Kalos Management Inc. raised its position in Chemed Corp. by 0.7% in the 2nd quarter. Kalos Management Inc. now owns 6,521 shares of the company’s stock worth $1,333,000 after purchasing an additional 45 shares during the last quarter. Finally, Coldstream Capital Management Inc. bought a new position in Chemed Corp. in the 2nd quarter worth approximately $229,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.
Chemed Corp. (CHE) traded down 2.49% during mid-day trading on Monday, reaching $199.69. The company had a trading volume of 91,590 shares. The company’s 50 day moving average is $196.75 and its 200 day moving average is $197.95. Chemed Corp. has a 52-week low of $132.92 and a 52-week high of $216.01. The stock has a market capitalization of $3.19 billion, a price-to-earnings ratio of 49.54 and a beta of 1.13.
Chemed Corp. (NYSE:CHE) last posted its earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.89 by $0.26. Chemed Corp. had a net margin of 4.16% and a return on equity of 26.18%. The company had revenue of $415.06 million during the quarter, compared to analysts’ expectations of $407.56 million. During the same quarter in the previous year, the company posted $1.80 earnings per share. Chemed Corp.’s quarterly revenue was up 6.3% compared to the same quarter last year. Equities analysts predict that Chemed Corp. will post $8.21 earnings per share for the current year.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.